论文部分内容阅读
目的研究细胞周期蛋白D1(cyclinD1)和肿瘤转移抑制基因(nm23)在宫颈癌新辅助化疗中表达的意义。方法免疫组化方法检测100例局部晚期宫颈癌组织中cyclinD1和nm23的表达水平。其中50例接受新辅助化疗的为观察组,50例未接受任何化疗的为对照组。结果接受新辅助化疗的观察组中cyclinD1蛋白表达较对照组高,统计学上有统计学差异(P<0.05)。nm23在两组间差异不大(P>0.05);cy-clinD1和nm23的阳性表达统计学上无统计学差异(P>0.05)。结论免疫组化检测cyclinD1可作为新辅助化疗在局部晚期宫颈癌中疗效的评估指标。nm23不能作为评估指标。
Objective To investigate the expression of cyclinD1 and nm23 in neoadjuvant chemotherapy of cervical cancer. Methods The expressions of cyclinD1 and nm23 in 100 cases of locally advanced cervical cancer were detected by immunohistochemistry. 50 cases received neoadjuvant chemotherapy for the observation group, 50 cases did not receive any chemotherapy for the control group. Results The expression of cyclinD1 protein in the observation group receiving neoadjuvant chemotherapy was significantly higher than that in the control group (P <0.05). There was no significant difference in the expression of nm23 between the two groups (P> 0.05). The positive expression of cy-clinD1 and nm23 showed no statistical difference (P> 0.05). Conclusion Immunohistochemical detection of cyclinD1 can be used as a neoadjuvant chemotherapy in the evaluation of the efficacy of locally advanced cervical cancer. nm23 can not be used as evaluation index.